Sign in

Markets

Overview
News
World markets
Treasuries
Currencies
Commodities
Economy

Stocks

Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers

ETFs

Overview
Popular funds
Most active
Gainers
Losers
News

Research

Search
Sectors

Articles published by Cabaletta Bio

< Previous 1 2 Next >

Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

January 29, 2025

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

January 13, 2025

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

November 26, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

November 18, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

November 14, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

November 06, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

September 25, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

August 28, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

August 08, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

July 02, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

June 14, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 29, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 15, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 13, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 21, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis

March 20, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

February 27, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

February 01, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 31, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis

January 08, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

November 28, 2023

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

November 09, 2023

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis

November 06, 2023

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

October 30, 2023

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201

October 02, 2023

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

September 19, 2023

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

August 30, 2023

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201

August 22, 2023

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

August 10, 2023

From Cabaletta Bio

Via GlobeNewswire

Tickers CABA

< Previous 1 2 Next >

© 2026 FinancialContent Services, Inc. All rights reserved.

Privacy Policy Terms of Service About

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.